accountIt looks like investors will have to wait a little longer to get news about Eli Lilly's (NYSE: LLY) potentially game-changing pipeline compound prasugrel. On Monday, the FDA pushed back its target review date for Lilly's marketing application of the heart drug by three months, to Sept. 26.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Why the Lilly Delay, FDA?
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
